Specific expression of hepatocyte nuclear factor-1β in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis

Cancer Science

Volumn 98, Issue 3, 2007, Pages 387-391

  Higashiguchi, Atsushi ^a   Yamada, Taketo ^a   Susumu, Nobuyuki ^a   Mori, Taisuke ^a   Suzuki, Atsushi ^a   Aoki, Daisuke ^a   Sakamoto, Michiie ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1BETA; MESSENGER RNA;

ARTICLE; ASCITES; CANCER CYTODIAGNOSIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MESOTHELIUM CELL; MUCINOUS CARCINOMA; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA, CLEAR CELL; CELL LINE, TUMOR; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33846684691     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00398.x     Document Type: Article

References (37)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
2. Holschneider CH, Berek JS. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19: 3-10.
3. Boyle P, Maisonneuve P, Autier P. Towards cancer control in women. J Epidemiol Biostat 1998; 3: 137-68.
4. Berek JS, Hacker NF. Practical Gynecologic Oncology, 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 2000.
5. Goff BA, Mandel LS, Muntz HG, Melancon CH. Ovarian cancer diagnosis: results of a national ovarian cancer survey. Cancer 2000; 89: 2068-75.
6. Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S. Symptoms of ovarian cancer. Obstet Gynecol 2001; 98: 212-17.
7. Smith EM, Anderson B. The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer 1985; 56: 2727-32.
8. Lee KR, Russell P, Tavassoli FA, et al. Surface epithelial stromal tumors. In: Tavassoli FA, Devilee P, eds. WHO Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon: IARC Press, 2003; 117-145.
9. Enomoto T, Kuragaki C, Yamasaki M et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 2003; 22: 447.
10. O'Brien MER, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): Bad prognosis only in early stages. Gynecol Oncol 1993; 49: 250-4.
11. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 5th edn. New York: Springer-Verlag, 2002, 791-804.
12. Kocjan G. Atras of Diagnostic Cytopathology, 2nd edn. New York: Churchill Livingstone, 1997.
13. Atahan S, Ekinci C, Icli F, Erdogan N. Cytology of clear cell carcinoma of the female genital tract in fine needle aspirates and ascites. Acta Cytol 2000; 44: 1005-9.
14. Ito H, Hirasawa T, Yasuda M, Osamura RY, Tsutsumi Y. Excessive formation of basement membrane substance in clear-cell carcinoma of the ovary: diagnostic value of the 'raspberry body' in ascites cytology. Diagn Cytopathol 1997; 16: 500-4.
15. Laucirica R, Schultenover SJ. Body cavity fluids. In: Ramzy I, ed. Clinical Cytopathology and Aspiration Biopsy, 2nd edn. New York: McGraw-Hill; 2005: 205-25.
16. Bohn S, Thomas H, Turan G et al. Distinct molecular and morphogenetic properties of mutations in the human HNF1β gene that lead to defective kidney development. J Am Soc Nephrol 2003; 14: 2033-41.
17. Coffiner C, Gresh L, Fiette L et al. Bile system morphogenesis defects and liver dysfunction upon targeted deletion of HNF1β. Development 2002; 129: 1829-38.
18. Tsuchiya A, Sakamoto M, Yasuda J et al. Expression profiling in ovarian clear cell carcinoma: Identification of hepatocyte nuclear factor-1β as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003; 163: 2503-12.
19. Schwartz DR, Kardia SL, Shedden KA et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002; 62: 4722-9.
20. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1β (HNF-1β) in clear cell tumors and endometriosis of the ovary. Mod Pathol 2006; 19: 83-9.
21. Sheibani K, Esteban JM, Bailey A, Battifora H, Weiss LM. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 1992; 23: 107-16.
22. Tamada Y, Iida S, Aoki D, Nozawa S, Irimura T. Carbohydrate epitopes and mucins expressed by 17 human ovarian carcinoma cell lines. Oncol Res 1999; 11: 233-41.
23. Nozawa S, Tsukazaki K, Sakayori M, Jeng CH, Iizuka R. Establishment of a human ovarian clear cell adenocarcinoma cell line (RMG-I) and its single cell cloning -With special reference to the stem cell of the tumor. Hum Cell 1988; 1: 426-35.
24. Hirasawa A, Saito-Ohara F, Inoue J et al. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003; 9: 1995-2004.
25. Terasawa K, Toyota M, Sagae S et al. Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br J Cancer 2006; 94: 914-21.
26. Cheng W, Liu J, Yoshida H, Rosen D, Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005; 11: 531-7.
27. Vallet V, Bens M, Antoine B et al. Transcription factors and aldolase B gene expression in microdissected renal proximal tubules and derived cell lines. Exp Cell Res 1995; 216: 363-70.
28. Rhoads DB, Rosenbaum DH, Unsal H, Isselbacher KJ, Levitsky LL. Circadian periodicity of intestinal N+/glucose cotransporter1 mRNA levels is transcriptionally regulated. J Biol Chem 1998; 273: 9510-16.
29. Lee YH, Magnuson MA, Muppala V, Chen SS. Liver-specific reactivation of the inactivated Hnf-1α gene. Elimination of liver dysfunction to establish a mouse MODY3 model. Mol Cell Biol 2003; 23: 923-32.
30. Hiraiwa H, Pan CJ, Lin B, Akiyama TE, Gonzalez FJ, Chou JY. A molecular link between the common phenotypes of type 1 glycogen storage diasease and HNF-1β-null mice. J Biol Chem 2001; 276: 7963-7.
31. Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol 1994; 11: 237-45.
32. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: Stepwise logistic regression analysis. Cytopathology 2000; 11: 8-17.
33. Davidson B, Risberg B, Kristensen G et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch 1999; 435: 43-9.
34. Barberis MC, Faleri M, Veronese S, Casadio C, Viale G. Calretinin: A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 1997; 41: 1757-61.
35. McCluggage WG, Maxwell P, Veenstra H, Frick CE, Laeng RH, Tiltman AJ. Monoclonal antibody SM047 as an immunohistochemical marker of ovarian adenocarcinoma. Histopathol 2001; 38: 542-9.
36. Sato S, Okamoto S, Ito K, Konno R, Yajima A. Differential diagnosis of mesothelial and ovarian cancer cells in ascites by immunocytochemistry using Ber-EP4 and calretinin. Acta Cytol 2000; 44: 485-8.
37. Okamoto S, Ito K, Sasano H. Ber-EP4 and anti-calretinin antibodies: A useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells. Tohoku J Exp Med 2005; 206: 31-40.